AeroLeads people directory · profile

Firas Younis Email & Phone Number

CEO of NOXON for the treatment of Idiopathic pulmonary fibrosis (IPF) at Noxon Inc.
Location: Haifa District, Israel 9 work roles 4 schools
LinkedIn matched
✓ Verified August 2026 3 data sources Profile completeness 86%

Contact Signals

LinkedIn Profile matched
3 free lookups remaining · No credit card
Current company
Noxon Inc.
Role
CEO of NOXON for the treatment of Idiopathic pulmonary fibrosis (IPF)
Location
Haifa District, Israel

Who is Firas Younis? Overview

A concise factual answer block for searchers comparing this professional profile.

Quick answer

Firas Younis is listed as CEO of NOXON for the treatment of Idiopathic pulmonary fibrosis (IPF) at Noxon Inc., based in Haifa District, Israel. AeroLeads shows a matched LinkedIn profile for Firas Younis.

Firas Younis previously worked as Chief Executive Officer at Noxon Inc. and Business and Research Development Manager at Patho-Logica – Experimental Pathology Services Laboratory. Firas Younis holds Doctor Of Philosophy (Ph.D.), Pharmacology from Tel Aviv University.

Profile bio

About Firas Younis

As DMPK nonclinical Lead at Teva pharmaceutical I managed 3 projects extended over different product development phases, including: Managing all preclinical DMPK/ADME activities of the project during development, starting from proof of concept, conducting and planning none-GLP and GLP IND-enabling PK studies at different CROs all over the world. Working closely with different functional groups including nonclinical safety, pharmacology and bioanalytics to ensure providing results within timelines while avoiding falling on project critical path. Worked with clinical pharmacology team, providing essential support for first in human studies/clinical phase 1; clinical dose selection based on preclinical obtained data, PK NCA analysis of clinical data and support decision making on dose escalation. Support advanced clinical phases 3 on PK sample transfers from clinical sites, samples bioanalysis, and data transfer. Nonclinical ADME regulatory documents writing and preparation; IND, IB, DSUR, and NDA. Preparation of briefing book (BB) for type B/C guidance meetings with FDA, mitigating with FDA, and participating in a type C meeting with the agency. additionally, have vast experience in PK/PD assessment of pharmacological agents in the treatment of various diseases; hypertension, diabetes, metabolic syndrome, multiple sclerosis, Alzheimer's, pain, close head injury, depression and anxiety. Developed in vivo models, as well as, assessment methods for such pathologies which included, behavioral and clinical manifestation, ADME and toxicological profiling of drugs, and assessment of gene modification at tissue levels. Experience at molecular pan of work included, PCR, RT-PCR, ELISA, RIA, and western blot.specialties: pharmaceutical drug development from preclinical upto first in human

Current workplace

Firas Younis's current company

Company context helps verify the profile and gives searchers a useful next step.

Noxon Inc.
Noxon Inc.
CEO of NOXON for the treatment of Idiopathic pulmonary fibrosis (IPF)
9 roles · 22 years

Firas Younis work experience

A career timeline built from the work history available for this profile.

Chief Executive Officer

Current
Noxon Inc.

Idiopathic pulmonary fibrosis (IPF) is a devastating disease of unknown etiology characterized by progressive fibrosis of the lungs leading to respiratory failure and death with a median survival of about 3 years consequent to diagnosis. Other lung fibrosis is a prominent feature of multiple diverse diseases, including connective tissue related interstitial lung disease, sarcoidosis, non-specific interstitial pneumonia (NSIP), drug and toxin-induced lung disease and occupational lung diseases such as silicosis. The company's research is focused on finding a potential therapy for such disease. Currently, available treatments are limited with several unwanted side effects, rendering patients with such pathologies undertreated. NOXON's is dedicated into the development of a therapeutic product for IPF using unique antioxidant platform, which was shown through many preliminary studies to be effective and has no side effects.

Jan 2023 - Present

Business And Research Development Manager

Ness Ziona, Israel, Il

As head of the non-clinical services at Patho-logica, we offer a full management of your project, as your project is important to us. We provide a professional, tailored study design to meet your objectives and achieve the project’s goals based on scientific merits, performance feasibility while targeting precise and deliverable end points. Our services include scientific professional consultation, designing and selection of suitable experimental model, and orchestrating comprehensive study protocol meeting study objectives. As it is our objective to meet the client satisfaction, Patho-logica offer full management of the project, prior, during and at end of the study at competitive cost and timeline. Whether it is a POC study design or advanced PK, ADME or toxicity complex design, we have the knowhow to meet your objectives. We have vast expertise in model development and drug delivery for variety of indications, as well as proficiency in pharmaceutical development and regulatory requirements needed to bring your product from the bench of your laboratory to clinical development.”

Jun 2021 - Jan 2023

Manager, Dmpk Project Lead

Tel-Aviv, Il

As DMPK nonclinical Lead at Teva pharmaceutical I managed 3 projects extended over different product development phases, including: Managing all preclinical DMPK/ADME activities of the project during development, starting from proof of concept, conducting and planning none-GLP and GLP IND-enabling PK studies at different CROs all over the world. Working closely with different functional groups including nonclinical safety, pharmacology and bioanalytics to ensure providing results within timelines while avoiding falling on project critical path. Worked with clinical pharmacology team, providing essential support for first in human studies/clinical phase 1; clinical dose selection based on preclinical obtained data, PK noncompartmental analysis of clinical data and support decision making on dose escalation. Support advanced clinical phases 3 on PK sample transfers from clinical sites, samples bioanalysis, and data transfer. Nonclinical ADME regulatory documents writing and preparation; IND, IB, DSUR, and NDA. Preparation of briefing book (BB) for type B/C guidance meetings with FDA, mitigating with FDA, and participating in a type C meeting with the agency.

Nov 2015 - Jan 2021

Project Leader

Tel Aviv, Il

Managing, directing and supervising a collaborate project with a pharmaceutical company, Boehringer Ingelheim- Germany. Examining the cardiac, pancreatic and kidney protection effects of a a drug designed for the treatment of diabetes through facillitating excess glucose secretion through urine. Responsibilies include planning and design, protocol writing,managing timeline and cost, financial estimation and budget allocation, supervision of work, procedures and data collection with defined quality assurance guidelines, data analysis, managing stakeholders, and comprehensive reports and other publications.

Apr 2013 - Jul 2015

Pre-Clinical Research Director

Ness Ziona, Il

Directing and managing several preclinical projects in different research themes; inculing planning, supervision of the the excecution, monitoring and maintaining conduct in accord with quality assuarance guidlines/GLP standards.

Feb 2012 - May 2013

Research Scientist/Project Director

Tel Aviv, Il

Study initiation, including planning and design followed by the writing of study proposition, study price estimate and monetory allocation of the funds (more than $0.5M). Managing the time line of the study, including submission. Drug development and preclinical research for key Pharmaceutical industries, including Bohrenger Ingelheim, USA and Germany, Bioline-Israel, and other academic institues including the Weizmann institute Science.

Oct 2005 - Feb 2012

Outsourced Project Leader

Ingelheim Am Rhein, Rhineland-Palatinate, De

Recruited Project leader to investigate further properties of the drugs for hypertension and diabetes provided by BI, in the form of academic CRO. Work performed at Tel Aviv University, Medical School. As project leader, I coordinated all activities of planing, designing, protocol writing, financial estimate and cost allocation, managing internal and external sources, managing project timeline- ensuring coherent work flow, managing the communication with the sponsor's (BI) delegated scientists, and finally responsible for data/finding reporting to sponsor in formal reports. Attended international conference during the projects, presenting research findings.

2005 - 2012 ~7 yrs

Project Director At Tau

Biolinerx

worked on collaborate project with BiolineRx to determine efficacy of a pharmacological agent on diabetes and hypertension, at the lab of Professor Talma Rosenthal

2005 - 2006 ~1 yr

Research Scientist/Team Leader

D-Pharm

Worked at the department of Pharmacology during which I was in charge of developing new in vivo and in vitro pharmacological models for experimental research in the field of neurodegenrative diseases inculding MS, PD, AD and pain. New drug PK/PD profiling, including drug distribution and penetration of the BBB using radioactive materials and markers. As a team leader, my resposibilties included scientific protocol writing, experimental design and planning, and assuring the progression of the experiment while exploiting all means available. Results and reports were presented to the management in the form oral presentation and written reports.

Jan 2000 - Aug 2003
4 education records

Firas Younis education

Doctor Of Philosophy (Ph.D.), Pharmacology

Tel Aviv University

Complete Course For Pmp, Project Managment

Technion - Israel Institute Of Technology

Master’S Degree, Pharmacology- Neuroscience And Head Trauma

The Hebrew University Of Jerusalem

Bachelor’S Degree, Biochemistry

Washington State University
FAQ

Frequently asked questions about Firas Younis

Quick answers generated from the profile data available on this page.

What company does Firas Younis work for?

Firas Younis works for Noxon Inc..

What is Firas Younis's role at Noxon Inc.?

Firas Younis is listed as CEO of NOXON for the treatment of Idiopathic pulmonary fibrosis (IPF) at Noxon Inc..

Where is Firas Younis based?

Firas Younis is based in Haifa District, Israel while working with Noxon Inc..

What companies has Firas Younis worked for?

Firas Younis has worked for Noxon Inc., Patho-Logica – Experimental Pathology Services Laboratory, Teva Pharmaceuticals, Tel Aviv University, and Pharmaseed Ltd.

How can I contact Firas Younis?

You can use AeroLeads to view verified contact signals for Firas Younis at Noxon Inc., including work email, phone, and LinkedIn data when available.

What schools did Firas Younis attend?

Firas Younis holds Doctor Of Philosophy (Ph.D.), Pharmacology from Tel Aviv University.

Find 750M verified contacts

Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.